Dihydrocapsiate does not increase energy expenditure nor fat oxidation during aerobic exercise in men with overweight/ obesity: a randomized, triple-blinded, placebo-controlled, crossover trial
Metadatos
Mostrar el registro completo del ítemAutor
Osuna Prieto, Francisco Javier; Acosta, Francisco M.; Pérez de Arrilucea Le Floc'h, Unai A.; Riquelme Gallego, Blanca; Merchán Ramírez, Elisa; Xu, Huiwen; Cruz Márquez, Juan Carlos De La; Amaro Gahete, Francisco José; Llamas Elvira, José Manuel; Triviño Ibáñez, Eva María; Segura Carretero, Antonio; Ruiz Ruiz, JonatanEditorial
Taylor & Francis
Materia
Capsinoids TRPV1 Obesity Nutraceutical FATmax Metabolism
Fecha
2022-07-19Referencia bibliográfica
Francisco J. Osuna-Prieto... [et al.] (2022) Dihydrocapsiate does not increase energy expenditure nor fat oxidation during aerobic exercise in men with overweight/obesity: a randomized, tripleblinded, placebo-controlled, crossover trial, Journal of the International Society of Sports Nutrition, 19:1, 417-436, DOI: [10.1080/15502783.2022.2099757]
Patrocinador
Spanish Junta de Andalucia via Consejeria de Conocimiento, Investigacion y Universidades, Proyectos I+D+i del Programa Operativo del Fondo Europeo de Desarrollo Regional (FEDER 2018) B.CTS.377.UGR18; Spanish Government PTA 12264-I FPU16/02828 FPU16/05159Resumen
Background: Prior evidence suggests that capsinoids ingestion may
increase resting energy expenditure (EE) and fat oxidation (FATox), yet
whether they can modulate those parameters during exercise conditions
remains poorly understood. We hypothesized that dihydrocapsiate
(DHC) ingestion would increase EE and specifically FATox during an
acute bout of aerobic exercise at FATmax intensity (the intensity that
elicits maximal fat oxidation during exercise [MFO]) in men with overweight/
obesity. Since FATmax and MFO during aerobic exercise
appear to be indicators of metabolic flexibility, whether DHC has an
impact on FATox in this type of population is of clinical interest.
Methods: A total of 24 sedentary men (age = 40.2 ± 9.2 years-old;
body mass index = 31.6 ± 4.5 kg/m2 [n = 11 overweight, n = 13
obese]) participated in this randomized, triple-blinded, placebocontrolled,
crossover trial (registered under ClinicalTrials.gov
Identifier no. NCT05156697). On the first day, participants underwent
a submaximal exercise test on a cycle ergometer to determine their MFO and FATmax intensity during exercise. After 72 hours had
elapsed, the participants returned on 2 further days (≥ 72 hours
apart) and performed a 60 min steady-state exercise bout (i.e. cycling
at their FATmax, constant intensity) after ingesting either 12 mg of
DHC or placebo; these conditions were randomized. Respiratory gas
exchange was monitored by indirect calorimetry. Serum marker
concentrations (i.e. glucose, triglycerides, non-esterified fatty acids
(NEFAs), skin temperature, thermal perception, heart rate, and perceived
fatigue) were assessed.
Results: There were no significant differences (P > 0.05) between
DHC and placebo conditions in the EE and FATox during exercise.
Similarly, no significant changes were observed in glucose, triglycerides,
or NEFAs serum levels, neither in the skin temperature nor
thermal perception across conditions. Heart rate and perceived
fatigue did not differ between conditions.
Conclusions: DHC supplementation does not affect energy metabolism
during exercise in men with overweight/obesity.